SEATTLE – Oct. 22, 2014 – Fred Hutch’s Obliteride proves it’s serious about helping end cancer. In its second year, the bike ride raised $2.25 million for lifesaving research at Fred Hutchinson Cancer Research Center in Seattle.
“We’re thrilled our riders worked hard to raise these vital funds,” said Amy Lavin, Obliteride’s executive director. “It’s time our community rallied around this amazing research center we’re fortunate to have here in the Northwest.”
Nearly 1,000 people rode more than 60,000 miles in the August event. “Obliteride is more than a bike ride,” said Lavin. “It’s a fun weekend of concerts, celebration and connection toward a common goal.”
“Obliteride is a way for our entire community to be part of Fred Hutch’s mission to end cancer,” said Dr. Fred Appelbaum, executive vice president and deputy director of Fred Hutch. “Private donations are more critical now than ever because of federal cutbacks. Funding is essential; lives are counting on it.”
Obliteride donations will support various forms of cancer research, including breast and other solid tumor cancers. A portion of Obliteride funds also will be designated to catalyze some of the newest and most promising cancer research.
Obliteride’s generous sponsors, including University Village and the Sloan Foundation, ensure 100 percent of every dollar raised stays right here in our community and goes directly to research at Seattle’s Fred Hutch.
Save the date for the next Obliteride: Aug. 9, 2015. Details will be announced in early January when registration opens. For more information, visit www.obliteride.org.
Obliteride is a community that cares fiercely about ending cancer. We connect over the impact cancer is having on our lives and our intense commitment to find better treatments and ultimately eliminate it. We believe that together we can make a difference. Together we can end cancer. Join the movement to obliterate cancer. It’s fun, focused and full of energy! 100% of every dollar raised goes directly to lifesaving cancer research at Fred Hutch.